Physician profile
Russ Daniel Hopper
NPI 1598248643
$1,965.20
in general payments reported to CMS, 2019-2025
26 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.89 · 2022: $202 · 2023: $442 · 2024: $582 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665 · Entertainment: $13.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.50 |
| Entertainment | $13.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.79 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $158.37 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $148.81 | 2023-2025 | Veozah |
| Lilly USA, LLC | $147.28 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $142.17 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $127.38 | 2022-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $108.11 | 2022-2025 | |
| Dexcom, INC. | $101.37 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $88.33 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $63.36 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.10 | 2022-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $43.07 | 2024-2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $36.54 | 2021-2023 | Ultomiris |
| Exact Sciences Corporation | $36.48 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $34.39 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $23.40 | 2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $21.71 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $20.48 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $20.33 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $17.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.73 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $14.65 | 2021 | |
| Ibsa Pharma INC. | $14.49 | 2025 | Tirosint, Licart, Flector |
| Optos, INC. | $13.97 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Corium, LLC | $10.11 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russ Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.